Page last updated: 2024-10-25

cilostazol and Liver Steatosis

cilostazol has been researched along with Liver Steatosis in 4 studies

Research Excerpts

ExcerptRelevanceReference
"All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group."3.74Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. ( Abe, Y; Endo, H; Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Kobayashi, N; Kubota, K; Nagashima, Y; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Wada, K; Yoneda, M, 2008)
"Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance."1.56Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020)
"Nonalcoholic fatty liver disease (NAFLD) is an increasingly studied condition that can progress to end-stage liver disease."1.48Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK. ( Choi, Y; Kim, HY; Kwon, WY; Lee, MH; Lee, SY; Nam, TG; Oh, YJ; Suh, SH; Yoo, YH, 2018)
"Cilostazol treatment ameliorated lipid accumulation induced by palmitate, and this effect was diminished when ABCA1 or LRP1 was silenced by small interference RNA."1.42Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. ( Cha, BS; Jeon, BH; Kang, ES; Kim, SH; Lee, BW; Lee, HC; Lee, YH; Yun, MR, 2015)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
El-Deen, RM1
Heeba, GH1
Abdel-Latif, RG1
Khalifa, MMA1
Oh, YJ1
Kim, HY1
Lee, MH1
Suh, SH1
Choi, Y1
Nam, TG1
Kwon, WY1
Lee, SY1
Yoo, YH1
Jeon, BH1
Lee, YH1
Yun, MR1
Kim, SH1
Lee, BW1
Kang, ES1
Lee, HC1
Cha, BS1
Fujita, K1
Nozaki, Y1
Wada, K1
Yoneda, M1
Endo, H1
Takahashi, H1
Iwasaki, T1
Inamori, M1
Abe, Y1
Kobayashi, N1
Kirikoshi, H1
Kubota, K1
Saito, S1
Nagashima, Y1
Nakajima, A1

Other Studies

4 other studies available for cilostazol and Liver Steatosis

ArticleYear
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
    Fundamental & clinical pharmacology, 2020, Volume: 34, Issue:3

    Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I

2020
Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK.
    Molecular pharmacology, 2018, Volume: 94, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cilostazol; Diet, High-Fat; Down-Regulatio

2018
Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis.
    Metabolism: clinical and experimental, 2015, Volume: 64, Issue:11

    Topics: Animals; Apoptosis; ATP Binding Cassette Transporter 1; Cilostazol; Diet, High-Fat; Fatty Liver; Hep

2015
Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease.
    Gut, 2008, Volume: 57, Issue:11

    Topics: Alanine Transaminase; Animals; Aspirin; Cholesterol; Choline Deficiency; Cilostazol; Dietary Fats; D

2008